N6-甲基腺苷介导的FZD10上调通过WNT/β-catenin和Hippo信号通路调控肝癌干细胞特性及仑伐替尼耐药
研究探讨FZD10在肝癌干细胞及仑伐替尼耐药中的作用机制。METTL3依赖的m6A甲基化上调FZD10,激活β-catenin和YAP1促进干细胞自我更新、成瘤和转移,并形成正反馈环路。FZD10/β-catenin/c-Jun/MEK/ERK轴决定仑伐替尼反应,靶向FZD10或β-catenin抑制剂可恢复耐药肝癌对仑伐替尼的敏感性。
要点
- METTL3介导的m6A甲基化上调肝癌干细胞中FZD10表达。
- FZD10通过激活β-catenin和YAP1促进肝癌干细胞自我更新、成瘤和转移。
- 靶向FZD10或使用β-catenin抑制剂可恢复耐药肝癌对仑伐替尼的敏感性。
核心结论
- FZD10表达升高促进肝癌干细胞扩增和仑伐替尼耐药,提示FZD10表达是新型预后生物标志物和治疗靶点。
研究设计与样本
- 研究通过RNA测序鉴定肝癌干细胞中FZD10表达,并用实时聚合酶链反应和免疫组化验证;采用体外和体内实验评估FZD10对肝癌干细胞扩增和仑伐替尼耐药的影响;应用RNA测序、RNA结合蛋白免疫沉淀和荧光素酶报告实验探索机制;分析患者队列、患者来源肿瘤类器官和患者来源异种移植瘤。
主要发现
- 肝癌干细胞中FZD10的激活由METTL3依赖的FZD10信使RNA的N6-甲基腺苷甲基化介导。
- FZD10通过激活β-catenin和YAP1促进肝癌干细胞自我更新、成瘤性和转移。
- FZD10-β-catenin/YAP1轴在肝癌干细胞中激活并预测不良预后。
- FZD10-β-catenin/c-Jun轴转录激活METTL3表达,形成正反馈环路。
- FZD10/β-catenin/c-Jun/MEK/ERK轴决定肝癌细胞对仑伐替尼治疗的反应;患者队列、患者来源肿瘤类器官和患者来源异种移植瘤分析提示FZD10可能预测肝细胞癌患者仑伐替尼临床获益;靶向FZD10的腺相关病毒或β-catenin抑制剂治疗可恢复耐药肝癌对仑伐替尼的反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide, but there is a deficiency of early diagnosis biomarkers and therapeutic targets. Drug resistance accounts for most HCC-related deaths, yet the mechanisms underlying drug resistance remain poorly understood. METHODS: Expression of Frizzled-10 (FZD10) in liver cancer stem cells (CSCs) was identified by means of RNA sequencing and validated by means of real-time polymerase chain reaction and immunohistochemistry. In vitro and in vivo experiments were used to assess the effect of FZD10 on liver CSC expansion and lenvatinib resistance. RNA sequencing, RNA binding protein immunoprecipitation, and luciferase report assays were applied to explore the mechanism underlying FZD10-mediated liver CSCs expansion and lenvatinib resistance. RESULTS: Activation of FZD10 in liver CSCs was mediated by METTL3-dependent N6-methyladenosine methylation of FZD10 messenger RNA. Functional studies revealed that FZD10 promotes self-renewal, tumorigenicity, and metastasis of liver CSCs via activating β-catenin and YAP1. The FZD10-β-catenin/YAP1 axis is activated in liver CSCs and predicts poor prognosis. Moreover, FZD10-β-catenin/c-Jun axis transcriptionally activates METTL3 expression, forming a positive feedback loop. Importantly, the FZD10/β-catenin/c-Jun/MEK/ERK axis determines the responses of hepatoma cells to lenvatinib treatment. Analysis of patient cohort, patient-derived tumor organoids, and patient-derived xenografts further suggest that FZD10 might predict lenvatinib clinical benefit in patients with HCC. Furthermore, treatment of lenvatinib-resistant HCC with adeno-associated virus targeting FZD10 or a β-catenin inhibitor restored lenvatinib response. CONCLUSIONS: Elevated FZD10 expression promotes expansion of liver CSCs and lenvatinib resistance, indicating that FZD10 expression is a novel prognostic biomarker and therapeutic target for human HCC.
引用
- Wang J, Yu H, Dong W, et al. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways. Gastroenterology. 2023. PMID: 36764493. doi:10.1053/j.gastro.2023.01.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。